[1] 徐鹏.乏氧显像剂 18F-MISO的应用.实用医技杂志,2006,13:2110-2112. [2] Giaccia AJ. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol,1996,6:46-58. [3] Toma-Dasu I,Dasu A,Karlsson M. The relationship between temporal variation of hypoxia,polarographic measurements and predictions of tumour response to radiation. Phys Med Biol,2004,49:4463-4475. [4] 任延刚,尹立杰,丁田贵,等.高压氧与立体定向放疗联合治疗晚期胰腺癌临床观察.中国基层医药,2005,12:349-350. [5] Kizaka-Kondoh S,Itasaka S,Zeng L,et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res,2009,15:3433-3441. [6] 李国权,李小龙,谢冰冰,等.β-榄香烯对人肺腺癌裸鼠移植瘤照射增敏机制的研究.中华放射医学与防护杂志,2010,30:687-691. [7] Alber M,Paulsen F,Eschmann SM,et al.On biologically conformal boost dose optimization. Phys Med Biol,2003,48:31-35. [8] 梁培炎,王国慧,李群,等.99Tcm-HL91乏氧显像在鼻咽癌治疗中的应用.中华核医学杂志,2006,26:97-99. [9] Chao KS,Bosch WR,Mutic S,et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys,2001,49:1171-1182. [10] Grosu AL,Souvatzoglou M,Roper B,et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose paintingfor individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys,2007,69:541-551. [11] Kinuya S,Yokoyama K,Konoshi S,et al. Increased uptake of 99Tcm-HL91 in tumor cells exposed to X-ray radiation. Ann Nucl Med,2000,14:139-141. [12] Koh WJ,Bergman KS,Rasey JS,et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using[F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys,1995,33:391-398. [13] Pitson G,Fyles A,Milosevic M,et al. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys,2001,51:699-703. [14] Minn H,Gronroos TJ,Komar G,et al. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des,2008,14:2932-2942. [15] van Loon J,van Baardwijk A,Boersma L,et al. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev,2011,37:331-343. [16] Eschmann SM,Paulsen F,Reimold M,et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med,2005,46:253-260. [17] Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys,1998,42:701-704. [18] Evans SM,Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett,2003,195:1-16. [19] Sorensen A,Pedersen M,Tietze A,et al. BOLD MRI in sheep fetuses: a non-invasive method for measuring changes in tissue oxygenation. Ultrasound Obstet Gynecol,2009,34:687-692. [20] Padhani A. Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia? Radiology,2010,254:1-3. [21] Chopra S,Foltz WD,Milosevic MF,et al. Comparing oxygen-sensitive MRI(BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol,2009,85:805-813. [22] Van De Wiele C,Versijpt J,Dierckx RA,et al.99Tc(m) labelled HL91 versus computed tomography and biopsy for the visualization of tumour recurrence of squamous head and neck carcinoma. Nucl Med Commun,2001,22:269-275. [23] Troost EG,Laverman P,Kaanders JH,et al. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-gluco-RGD autoradiography. J Nucl Med,2008,49:1732-1733. [24] 胡旭东,杨国仁,张鹏,等.99Tcm-HL-91乏氧显像监测放疗前后肿瘤乏氧状态的动物实验研究.现代肿瘤医学,2005,13:351-353. [25] Li L,Yu JM,Xing LG,et al. Hypoxic imaging with 99Tcm-HL91 single photon emission computed tomography in advanced non-small cell lung cancer. Chin Med J,2006,119:1477-1480. [26] Bayly SR,King RC,Honess DJ,et al. In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J Nucl Med,2008,49:1862-1868.
2012, Vol. 21 
